Accelerating Preclinical Testing for Multispecific Antibodies

Preclinical bottlenecks kill timelines. For translational medicine teams advancing multispecific antibodies toward IND filing, one of the most persistent obstacles is the gap between in vitro cytotoxicity data and in vivo non-human primate (NHP) studies. When a CD3-targeting binder lacks cross-reactivity with cynomolgus monkey CD3, teams must either engineer a surrogate molecule for NHP work or accept that their in vitro results will not translate cleanly into the animal models regulators expect. Nona Biosciences has addressed this problem at the platform level, building cross-reactive CD3 binders from fully human heavy-chain-only antibodies (HCAbs) that eliminate the need for surrogate engineering and compress the preclinical timeline.

The chain mispairing problem compounds this challenge for bispecific and multispecific formats. Conventional bispecific antibody manufacturing requires matching heavy and light chains from two distinct binding arms, creating mispairing combinations that reduce yield, complicate purification, and introduce manufacturing risk before a program ever reaches IND. Nona’s HBICE® (HCAb-Based Immune Cell Engager) platform resolves this structurally by using single-domain HCAb-derived binders that carry no light chain, eliminating mispairing by design rather than by engineering workaround.

Cross-Reactive CD3 Binders Compress the Preclinical Timeline

Cynomolgus cross-reactivity in a CD3 binder is not a convenience feature. It is a translational requirement. NHP toxicology and efficacy studies are a standard component of IND-enabling packages for T cell engagers, and regulators expect pharmacological activity in the NHP model to be driven by the same molecule that will enter the clinic. When a binder is human-specific, teams must develop and characterize a separate cynomolgus-reactive surrogate, adding months of engineering, expression, and characterization work before NHP studies can begin.

Nona Biosciences’ CD3 VH-2 binder, derived from the HBICE® platform, is the first reported CD3 agonistic binder with confirmed cynomolgus CD3 cross-reactivity. Affinity for both human and cynomolgus CD3 epsilon-delta heterodimeric protein has been demonstrated by ELISA, and functional activity in cynomolgus PBMCs has been confirmed in on-target cytotoxicity assays. In a direct comparison, a T cell engager containing CD3 VH-2 produced dose-dependent cytotoxicity in cynomolgus PBMCs at levels comparable to a TCE built on the SP34-derived CD3 Fab binder, a widely used benchmark. Critically, only baseline cytotoxic effects were observed on tumor cells negative for the tumor-associated antigen, confirming target-dependent activity and reducing the risk of off-target toxicity signals that could complicate NHP study interpretation.

The practical implication for preclinical scientists is direct: a single CD3 binder can be used across in vitro human PBMC assays and in vivo cynomolgus studies without modification. This eliminates a full engineering cycle from the preclinical workflow and removes a source of data discontinuity between species. Teams working under compressed timelines toward IND filing gain weeks to months of runway by avoiding surrogate molecule development entirely.

How Harbour Mice® Produce HCAbs Suited for Multispecific Preclinical Programs

Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies) are the foundation of Nona’s cross-reactive binder capability. The platform was developed by Dr. Frank Grosveld at Erasmus MC in 2006 and produces fully human HCAbs through natural in vivo immune selection, using human VH gene segments and a constant region lacking CH1. Over more than 20 years of optimization, Nona has refined the VH gene repertoire used in Harbour Mice® to nine human V genes selected specifically for developability, excluding sequences with high hydrophobicity or poor stability that would introduce manufacturing liabilities downstream.

The result is a discovery platform that consistently delivers HCAbs with sub-nanomolar to low nanomolar affinities, thermal stability with Tm values in the 55 to 60°C range, expression yields above 10 mg per liter in the majority of cases, and purity above 95%. These are not theoretical projections. They reflect empirical data from Nona’s discovery programs across hundreds of antibody discovery programs completed to date, with many molecules reaching clinical stage.

For multispecific formats specifically, the single-domain architecture of HCAb-derived binders provides structural flexibility that conventional IgG-based bispecific engineering cannot match. The AstraZeneca-partnered Claudin 18.2 x CD3 bispecific (AZD5863), currently in clinical development, illustrates this directly: the molecule incorporates two Claudin 18.2 HCAb VH domains alongside a CD3 binder in a compact, manufacturable format. This design is only achievable because heavy chain only antibodies (HCAb) function as independent building blocks without requiring light chain pairing. Developers working with conventional IgG-based bispecific formats face chain mispairing rates that reduce manufacturing yield and require additional purification steps. The HCAb architecture removes this constraint structurally.

Immunogenicity data from clinical testing further supports the translational readiness of HCAbs from Harbour Mice®. The anti-drug antibody (ADA) rate observed in clinical testing for HCAb molecules was 4.1%, with no impact on pharmacokinetics or efficacy. This compares favorably against humanized binders, which carry residual non-human residues from the engineering process and present a higher baseline immunogenicity risk. Fully human sequences produced through natural immune selection in Harbour Mice® are inherently compatible with human immune tolerance in a way that humanized sequences cannot replicate.

From Discovery to IND: Nona’s Integrated Preclinical Pathway

Cross-reactive binders and a developable discovery platform address two critical preclinical bottlenecks, but translational medicine leads need more than individual capabilities. They need a connected workflow from target to IND package. Nona’s integrated Idea-to-IND capabilities are structured to provide exactly this, spanning target validation, antigen preparation, immunization, antibody screening, lead generation, engineering, developability assessment, and pharmacological evaluation within a single integrated program.

The fully human antibody discovery workflow at Nona incorporates Beacon® (single B-cell screening instrument used for high-recovery HCAb isolation) for high-throughput single B-cell screening, enabling recovery of rare binders with the specific cross-reactivity profiles that preclinical programs require. For multispecific programs targeting CD3, this means screening directly for cynomolgus cross-reactivity as a primary selection criterion rather than as a secondary engineering objective.

Nona’s Hu-mAtrIx AI platform extends this further by guiding the incorporation of developability-optimized sequences during lead selection, reducing the probability of late-stage attrition from aggregation, instability, or expression failure. Developability assessment covers expression yield, thermal stability, aggregation resistance, and chemical liabilities early in the discovery process, before candidates advance to IND-enabling studies.

For translational medicine leaders evaluating platform partners, the HBICE® bispecific and multispecific engineering capability at Nona represents a concrete reduction in preclinical risk, not a marginal improvement in one assay format.

Choosing the Right Partner for Multispecific IND Programs

Multispecific antibody programs carry compounding risk at every preclinical stage. Chain mispairing reduces manufacturing yield. Species-specific binders require surrogate engineering. Humanized sequences introduce immunogenicity uncertainty. Each of these risks adds time and cost before a program reaches IND.

Partnering with Nona provides a structurally integrated solution to all three. The Harbour Mice® platform produces fully human HCAbs with confirmed developability profiles. The HBICE® platform eliminates chain mispairing through single-domain architecture. Cross-reactive CD3 binders enable direct translation from human in vitro assays to cynomolgus in vivo studies using the same molecule. And Nona’s integrated Idea-toward-IND capabilities connect every stage of preclinical development within a single program structure.

Translational medicine teams advancing T-cell engagers, TCR mimic antibodies & bispecific engineering toward IND filing can explore Nona’s bispecific antibody developability assessment services to understand how early-stage developability data can be structured to support a regulatory package.

Frequently Asked Questions

What additional preclinical complexity does a multispecific antibody introduce compared to a conventional monospecific?

Multispecific formats carry compounding technical risk that a single-target antibody does not: multi-target biology risk (each arm can drive independent, sometimes competing, pharmacology), asymmetric PK/PD between binding arms, species-translatability gaps that widen as more binding domains are added, and assay and CMC complexity that scales with the number of specificities in the molecule. Nona’s Idea-to-IND workflow addresses this by integrating discovery and toxicology from the outset, building mechanism-driven models, planning species and surrogate strategy early, and linking PK/PD data to analytics from the first design iteration. The goal is IND-ready design upfront rather than discovering asymmetric PK or species gaps late, when a redesign is expensive.

Beyond simple bispecifics, what molecular formats can be built on the HBICE® platform?

HBICE®’s single-domain, light-chain-free architecture supports formats well beyond the standard 1+1 bispecific. Nona’s clinical-stage AZD5863 (Claudin 18.2 x CD3), partnered with AstraZeneca, is a 2+2+1 format, two Claudin 18.2 HCAb binding domains, an optimized CD3 arm, and a silent Fc domain for half-life extension, all in a single manufacturable molecule. Because HCAb-derived domains function as independent building blocks, this same architecture extends to trispecific and other multi-domain configurations without the combinatorial mispairing penalty that constrains IgG-based multispecific engineering.

How long does discovery typically take from immunization to candidate binders?

For a standard program, Nona’s discovery timeline runs roughly two to three months from immunization to recovered binders, assuming target antigen is ready to go. Immunization and affinity maturation account for most of that window; the exact timeline depends on titer development in the Harbour Mice®. Programs that also want purified antibody characterization or in vitro functional validation before advancing candidates should plan for additional time beyond the initial two-to-three-month binder recovery window.

Beyond chain mispairing, what other developability risks commonly derail multispecific programs at the preclinical stage?

The most common gaps Nona sees when partners arrive mid-program rather than at the start: absent or incomplete developability profiling (candidates selected on affinity and epitope alone, without early assessment of aggregation propensity, deamidation/oxidation hotspots, or viscosity behavior); expression system decisions made without CMC input, where a molecule characterized in transient HEK293 material behaves differently once moved to a stable CHO system; and formulation screening deferred until after process lock, which is especially costly for programs targeting high-concentration subcutaneous delivery. Building developability and formulation assessment into lead selection, rather than treating them as downstream CMC problems, avoids re-characterization work and protects the IND timeline.

When should a multispecific program use non-GLP versus GLP toxicology studies?

Non-GLP tox work is the right tool early, for decision-enabling questions: candidate down-selection, modality risk profiling, and dose range finding. GLP studies are reserved for the IND-enabling safety package required for regulatory submission. Running GLP prematurely, before the design is locked, tends to be expensive and inflexible, and can lock in a suboptimal candidate. Running it too late, without adequate non-GLP groundwork, risks non-acceptable data, repeated studies, and IND delay.

Can the same discovery campaign support CAR-T, ADC, and multispecific programs at once?

Yes. This is the premise behind Nona’s HCAb+ platform, which treats the core HCAb architecture as a modular engine rather than a single-purpose antibody format. The same fully human single-domain binders can be routed into immune cell engagers and other multispecific biologics (“Plus Protein”), next-generation ADCs including bispecific ADCs (“Plus Payload”), or CAR-T, CAR-NK, and CAR-macrophage constructs (“Plus Cell”) from a single discovery campaign. For translational teams running parallel modality evaluations, this removes the need to launch separate discovery efforts for each format.

1. Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link

2. Suurs F.V. et al., A review of bispecific antibodies and antibody constructs in oncology and clinical challenges, Pharmacology and Therapeutics, 2019. Link

3. Mack M. et al., A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity, Proceedings of the National Academy of Sciences, 1995. Link

4. Hamers-Casterman C. et al., Naturally occurring antibodies devoid of light chains, Nature, 1993. Link

5. Desmyter A. et al., Camelid nanobodies: killing two birds with one stone, Current Opinion in Structural Biology, 2015. Link

6. Bernett M.J. et al., Immune cell engagers for hematologic malignancies, Seminars in Hematology, 2023. Link

7. Leong S.R. et al., An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia, Blood, 2017. Link

8. Spiess C. et al., Alternative molecular formats and therapeutic applications for bispecific antibodies, Molecular Immunology, 2015. Link